Novo Nordisk/LinkedIn
Oct 31, 2025, 14:21
Novo Nordisk Submits Biologics License Application for Mim8 (Denecimig) in Hemophilia A
National Bleeding Disorders Foundation (NBDF) shared on LinkedIn:
”Novo Nordisk has submitted a Biologics License Application (BLA) for Mim8 (denecimig), a promising bispecific antibody therapy for people with hemophilia A, with or without inhibitors.
Mim8 may offer more flexible dosing options and an easier treatment experience through a single-use, prefilled injector pen.
Learn more about this milestone”
Read the full announcement here.
Stay updated on the emerging with Hemostasis Today.
-
Jun 1, 2026, 11:16Ocima Richard Draza: Postpartum Hemorrhage – A Practical Step-by-Step Management Guide
-
Jun 1, 2026, 10:57Kyungjun Lim: How Will Future Mars Colonies Manage Their Supply Chains?
-
May 31, 2026, 16:29José Antonio García Erce: Collaborative PBM Implementation in Transfusion Centers and Services
-
May 31, 2026, 16:22Vera Ignjatović: How Do We Rigorously Study These Drugs in Children to Understand Their True Benefits and Risks?
-
May 31, 2026, 16:21Ksenija Stach: Is This The Future of Lipid-Lowering Lherapy?
-
May 31, 2026, 15:42Antonio Greco: Balancing Bleeding and Thrombotic Risk After PCI
-
May 31, 2026, 15:41Eric Topol: Replication of Plasma p-tau217 Blood Test for Predicting Alzheimer’s Disease
-
May 31, 2026, 15:32ASH Invites Dynamic Members to Apply for 2027 Leadership and Committee Roles
-
May 31, 2026, 14:39Monique Gore-Massy: Redefining Lupus Innovation Through Patient Partnership